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Case 21-2016: A Man in an Unresponsive State
To the Editor: In the case discussed by Fenves 
et al. (July 14 issue),1 a patient who had a negative 
test for hepatitis B virus (HBV) surface antigen 
and a positive test for HBV surface antibodies 
6 years earlier (with no previous testing for HBV 
core antibodies) presents with fulminant hepatic 
failure due to acute HBV infection, with positive 
tests for both HBV surface antigen and HBV core 
IgM antibodies. Reasonable explanations for this 
presentation are a false positive test for HBV sur-
face antibodies 6 years earlier or infection with a 
mutant strain of HBV. However, four points, main-
ly regarding the interpretation of serologic test-
ing for HBV, deserve attention. First, the inactive-
carrier state is defined by persistent positivity for 
HBV surface antigen; thus, a patient with a nega-
tive test for HBV surface antigen 6 years earlier 
cannot be an inactive carrier.2 Second, no HBV 
reactivation of any severity has been described in 
patients who are negative for HBV surface anti-
gen and do not receive immunosuppression.2 
Third, HBV DNA is not universally suppressed in 
patients who have HBV plus a superinfection 
with HDV; such patients may sometimes have high 
HBV DNA levels and may even be seropositive for 
HBV e antigen. In patients who have coinfection 
with HBV and HDV, HBV replication is present 
during the acute phase.3 Fourth, although the 
use of antibiotic and antifungal agents has not 
been consistently associated with increased sur-
vival in patients with acute liver failure, these 
agents are still administered as standard therapy 
in patients with encephalopathy or coagulopathy 
and organ failure.4
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The discussants reply: We agree with Tsochatzis 
and Papatheodoridis that inactive carriers have a 
detectable level of serum HBV surface antigen. 
The previous positive test for HBV surface anti-
bodies in this patient could have indicated either 
resolved acute infection or chronic infection that 
passed through an inactive-carrier phase with 
eventual clearance of serum HBV surface anti-
gen; either case could result in persistence of the 
intrahepatocytic replication-competent HBV ge-
nome, which could lead to later loss of immune 
control and reactivation of infection. Such reacti-
vation in the absence of immunosuppression is 
very rare but has been reported.1 Specific labora-
tory testing would certainly have allowed for a 
more definitive determination of the presence or 
absence of superinfection or coinfection with 
HDV, but the typical inverse relationship of the 
replicative levels of HDV and HBV in patients 
with HDV superinfection led to our speculation 
that acute HDV infection was unlikely in this pa-
tient with a high HBV viral load.
Although we agree with a low threshold for 
initiating antimicrobial agents in critically ill pa-
tients with acute liver failure, we do not believe 
that the use of prophylactic antibiotics should be 
a standard of care. Guidelines do not recom-
mend universal antimicrobial prophylaxis.2 Evi-
dence to suggest a survival benefit is lacking, 
and certain antimicrobials potentiate liver injury. 
Future research should aim to define whether a 
subset of patients could benefit from antimicro-
bial prophylaxis.
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